| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-06-26 | University of Cambridge (UK) Genomics England Ltd (UK) Illumina (USA) | 100,000 Genomes Project | rare genetic diseases, cancers | collaboration | Genetic diseases - Rare diseases - Cancer - Oncology | Collaboration agreement |
| 2017-06-26 | Takeda Pharmaceutical (Japan) Biological E. (India) | measles vaccines and acellular pertussis vaccine | measles, pertussis | licensing | Infectious diseases | Licensing agreement |
| 2017-06-19 | Txcell (France) Lentigen Technology (USA - MD), a wholly owned subsidiary of Miltenyi Biotech (Germany) | HLA?A2 CAR lentiviral vector | prevention of chronic rejection after organ transplantation | services contract manufacturing bioproduction | Transplantation | Services contract |
| 2017-06-15 | CitoxLab (France) KaLy-Cell (France) | in vitro and ex vivo testing for hepatotoxicity and metabolism | collaboration | Technology - Services | Collaboration agreement | |
| 2017-06-12 | Zealand Pharma (Denmark) Helsinn Healthcare (Switzerland) | elsiglutide | chemotherapy-induced diarrhea | termination of an agreement | Cancer - Oncology | Termination of an agreement |
| 2017-06-12 | Tiziana Life Sciences (UK) | nomination | Autoimmune diseases - Cancer - Oncology | Nomination | ||
| 2017-06-09 | Ascensia Diabetes Care (Switzerland) Voluntis (France) | insulin management solutions. | type 2 diabetes | development | Metabolic diseases | Development agreement |
| 2017-06-08 | Vertex Pharmaceuticals (USA - MA) | nomination | Rare diseases - Genetic diseases | Nomination | ||
| 2017-06-05 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-06-05 | Novartis (Switzerland) IBM Watson Health (USA - NY) | cognitive solution to provide insights on the expected outcomes of breast cancer treatment options | breast cancer | collaboration | Cancer - Oncology | Collaboration agreement |
| 2017-06-02 | BMS (USA - NY) Seattle Genetics (USA - WA) | Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) | relapsed or refractory Hodgkin lymphoma, relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-06-02 | Innate Pharma (France) Novo Nordisk (Denmark) | anti-C5aR (IPH5401) | product acquisition | Cancer - Oncology | Product acquisition | |
| 2017-05-31 | AstraZeneca (UK) | nomination | Nomination | |||
| 2017-05-31 | Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) | binimetinib and encorafenib | licensing, development, commercialisation | Licensing agreement | ||
| 2017-05-31 | Baxalta (USA - IL) Mayo Clinic (USA - MN) | research - R&D | Kidney diseases - Renal diseases | Research agreement | ||
| 2017-05-30 | Array BioPharma (USA - CO) BMS (USA - NY) | binimetinib in combination with Opdivo® (nivolumab) and Opdivo® + Yervoy® (ipilimumab) | metastatic colorectal cancer in patients with microsatellite stable tumors | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-23 | Nabriva Therapeutics (Austria) Nabriva Ireland (Ireland) | establishment of a new subsidiary in the EU | Infectious diseases | Establishment of a new subsidiary in the EU | ||
| 2017-05-16 | Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany) | NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab) | metastatic pancreatic cancer, metastatic colorectal cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-16 | Oryzon Genomics (Spain) | nomination | Nomination | |||
| 2017-05-15 | Akebia Therapeutics (USA - MA) Vifor Pharma (Switzerland) Fresenius Medical Care (Germany) | vadadustat | anemia associated with chronic kidney disease | licensing | Kidney diseases - Renal diseases | Licensing agreement |
